VENUS REMEDIES BAGS APPROVAL TO MARKET MEROPENEM, ITS BLOCKBUSTER GENERIC DRUG, IN SPAIN
The pharmaceutical world is abuzz as Venus Remedies Limited secures marketing authorization for meropenem in Spain. A leader in research-based pharmaceuticals, Venus Remedies is setting new benchmarks in healthcare.
Meropenem, part of the carbapenem class of antibiotics, is known for its broad-spectrum efficacy and is often used as a last resort in treating critical infections in intensive care units.
This authorization is a testament to Venus Remedies’ world-class manufacturing capabilities. The company has now set its sights on capturing 10% of the $6.34 million meropenem market in Spain, with plans to launch in December.
Meropenem has been a cornerstone for Venus Remedies, contributing to 40% of its total sales. The company’s international footprint is impressive, with over 120 marketing authorizations for meropenem in countries including the UK, Germany, Australia, UAE, and more.
Saransh Chaudhary, President of Global Critical Care at Venus Remedies, highlighted the importance of this development. He stated that this is an opportunity to solidify the company’s position in Europe and demonstrate its expertise in high-quality product development.
Furthermore, Akshansh Chaudhary, Executive Director of Venus Remedies, expressed optimism about future growth. He mentioned ongoing talks for more strategic alliances and anticipated a significant increase in turnover owing to marketing approvals across Europe.
With manufacturing facilities capable of producing 24 million units of meropenem annually and currently utilizing only 60% of this capacity, Venus Remedies is well-prepared to meet global demand.
Venus Remedies’ marketing authorization for meropenem in Spain is more than just a milestone; it’s an indication of the company’s unwavering commitment to global healthcare and its ability to drive innovation in the pharmaceutical sector.